As of 1 April, 2022, North Bristol NHS Trust has been designated as one of nine Specialised NHS England Complex Mesh Centres, supporting patients with mesh complications linked to urinary incontinence and vaginal prolapse in the South West.
These centres provide management of urinary incontinence and vaginal prolapse mesh complications, with the engagement of the multi-disciplinary team (MDT), which includes surgeons, physicians, imaging specialists, nurses, pain specialists, physiotherapists, and clinical psychologists in line with the published service specification.
The MDT of specialist clinicians is led by Professor Hashim, Consultant Urological Surgeon, and Mr. Madhu, Consultant Urogynaecologist.
Suspected complications following insertion of mesh for urinary incontinence or vaginal prolapse. This includes:
Referrals will be triaged by the Clinical Lead(s) and invited to an outpatient appointment. They will be referred to selected members of the MDT as required, and each patient will be discussed at the monthly MDT meeting. An outpatient appointment will then be arranged with the patient to discuss and agree their treatment plan.
Patient information leaflets and decision aids:
Please refer to Urogynaecology Mesh Complications via eRS (Urology) by completing the Mesh MDT referral form (also available as an EMIS template) and attaching copies of relevant clinic letters and investigations.
Bristol Mesh Complications Specialist Service Urogynaecology RAS – Southmead – RVJ (search under directory of services - Urology - (in) continence)
To contact us:
Telephone: Lynda Bishop, MDT coordinator for the Bristol Mesh Specialist Service: 0117 414 0899
Email: bristolmeshserviceadmin@nbt.nhs.uk
Efforts are made to ensure the accuracy and agreement of these guidelines, including any content uploaded, referred to or linked to from the system. However, BNSSG ICB cannot guarantee this. This guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer, in accordance with the mental capacity act, and informed by the summary of product characteristics of any drugs they are considering. Practitioners are required to perform their duties in accordance with the law and their regulators and nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.
Information provided through Remedy is continually updated so please be aware any printed copies may quickly become out of date.